8-K filing — Lantern Pharma Inc. (LTRN)
Filed: 2026-10-01 AccNo: 0001493152-26-045344 Size: 200 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Stocks · News reference
Lantern Pharma Announces Taiwan Approvals To Open Next Stage Of Phase 2 LP-300 Trial In Never-Smoker Lung Cancer
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lantern Pharma Issued Notice Of Allowance From U.S. Patent And Trademark Office For Application Titled Method For Treating Blood Cancers
Lantern Pharma Inc. (NASDAQ:LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and
Lantern Pharma Q2 2026 Earnings Call: Complete Transcript
Lantern Pharma (NASDAQ:LTRN) reported second-quarter financial results on Friday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by Benzinga